FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)Business Wire • 07/06/21
Mizuho: Merck withdrawing Keytruda as a gastric cancer treatment won't impact the stockMarket Watch • 07/02/21
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the USBusiness Wire • 07/01/21
NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic TargetsBenzinga • 07/01/21
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)Zacks Investment Research • 07/01/21
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29Business Wire • 06/30/21
Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to NormalcyPRNewsWire • 06/29/21
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 06/29/21
Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 06/27/21
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate CancerBusiness Wire • 06/24/21
Merck & Co, Inc. (MRK) Management Presents at Guggenheim Biopharma Strategy Series Conference Call (Transcript)Seeking Alpha • 06/22/21
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical CancerBusiness Wire • 06/22/21